Early-stage firms urged to run trials on 510(k) devices
This article was originally published in The Gray Sheet
Executive Summary
To boost sales and reimbursement, startups are "going to have to do the big clinical trial whether it's a 510(k) or a PMA, because you have got to prove to the market, in addition to the FDA, that the technology is valuable," Piper Jaffray Ventures Managing Director Buzz Benson asserts at the recent IBF/Medical Alley Medtech Investing Conference in Minneapolis. Startup firms also should focus on the appropriate setting for device use - be it inpatient, outpatient, home or ambulatory surgical centers. At a March meeting, venture capitalists urged startups to pursue reimbursement as early as possible (1"The Gray Sheet" March 8, 2004, p. 8)...
You may also be interested in...
Cautious Venture Capital Commands Medtech Start-Ups To Think Long-Term
A growing emphasis on evidence-based medicine is compelling medtech start-ups to seek consultation in developing a reimbursement strategy
Japan Grants Global-First Approval To Zolbetuximab With 15 New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.